Drug Patch Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs)

Drug Patch Tests, Enzyme-linked Immunosorbent Spot Assay (Elispot) and Lymphocyte Transformation Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs)

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03176342

Enrollment

Registered

2017-06-05

Start date

2016-08-04

Completion date

2017-08-03

Last updated

2017-06-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug Reaction

Keywords

Drug patch tests

Brief summary

The study is about drug patch tests in patients who have history of severe cutaneous drug reaction including Steven Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), Drug-induced eosinophilia and systemic symptoms (DRESS), AGEP (Acute generalized exanthematous pustulosis) and generalized bullous fixed drug eruptions. This study also investigate in Enzyme-linked immunosorbent spot assay (ELIspot) and lymphocyte transformation test. We also trying to prove the correlation among result of drug patch tests, ELIspot and LTT.

Interventions

OTHERpatch test

Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients with history of Steven Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug-induced eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), generalized bullous fixed drug eruption in the past 24 months. * Age more than 18 years old

Exclusion criteria

* Receiving immunosuppressive drugs or more than 10 mg/day of prednisolone within 1 month. * Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Prevalence of positive drug patch test results.	3 years

Secondary

Measure	Time frame
correlation of drug patch test results, ELIspot and lymphocyte transformation test.	3 years

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026